Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc said on Wednesday it had started the application process for its respiratory syncytial virus (RSV) vaccine, seeking approval to be used in older adults, with various regulators, including the United States and Europe.

Moderna starts application process for RSV vaccine approval in older adults

Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia The Company has also initiated a rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for mRNA-1345 mRNA-1345 met primary efficacy endpoints, demonstrating vaccine efficacy of 83.7% against RSV lower respiratory tract disease in older adults in the Phase 3 pivotal efficacy trial, ConquerRSV The Company plans further regulatory submissions for mRNA-1345 worldwide CAMBRIDGE, MA / ACCESSWIRE / July 5, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. The Company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia and has initiated the rolling submission process for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the licensure of the mRNA-based RSV vaccine.

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

Vaccine maker Moderna Inc said on Wednesday it had signed a memorandum of understanding and a land collaboration agreement to work towards opportunities for it to research, develop and manufacture mRNA medicines in China.

Moderna says it has signed deal in China with view to research and make mRNA medicines

Moderna recently asked regulators for authorization of its updated coronavirus vaccine. The company says it's ramped up production and is ready to deliver doses for the fall vaccination season.

Is Moderna Heading for a Critical Moment?

Advance Auto Parts

First Republic

KeyCorp

Pfizer

Zions Bancorp

The well's run dry for the sector thus far this year as energy prices stabilized.

Worst Stocks Of 2023's First Half: Battered Banks And Vaccine Makers

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.

Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab

U.S. biotech firm Moderna said on Monday it had submitted a regulatory application to the European Medicines Agency (EMA) seeking authorization for its updated COVID-19 vaccine to target the XBB.1.5 sub-variant.

Moderna files for European authorization of updated COVID vaccine

The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines Pending approval, Moderna's updated COVID-19 vaccine will be available for fall vaccination with ample and timely supply Preliminary clinical data show that the company's XBB1.5 monovalent vaccine induces an immune response against viruses of the XBB lineage CAMBRIDGE, MA / ACCESSWIRE / July 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a regulatory application to the European Medicines Agency (EMA) for its updated COVID-19 vaccine encoding the spike protein for the XBB.1.5 sublineage of SARS-CoV-2. "We are proud to announce this filing for our updated COVID-19 vaccine and continue to support the European Union in protecting citizens against COVID-19," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna NASDAQ: MRNA was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion as COVID-19 cases surged around the globe.

Moderna: Declining Performance And Relative Weakness

Is Moderna stock a buy after unveiling new results for its Merck-partnered cancer vaccine? Is MRNA stock a buy today?

Is Moderna Stock A Buy As It Doubles Down On Its Cancer Vaccine Efforts?

Alteryx

ChargePoint Holdings

CNH Industrial NV

Enphase Energy

Harley-Davidson

Nasdaq

NextEra Energy

Big Tech is having its best start to the year ever. But a different group of stocks may thrive in the second half.

Moderna and 7 More Stocks That Can Beat Apple in Second Half

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It

Novavax

Pharmaceutical stocks are trailing the market this year. So far in 2023, the Dow Jones U.S. Select Pharmaceuticals Index is down 5.4% while all three major indices are positive on the year.

3 Pharma Stocks That Have Big Investors Running for the Exit

Chewy

Lululemon Athletica

Some say we've entered a new bull market, but we may not be there yet. Still, there's a way to invest today that could help you win over time -- regardless of market conditions.

How to Invest $10,000 -- No Matter What the Market is Doing

Moderna Inc (NASDAQ: MRNA) has been in a sharp downtrend since the start of this year but a UBS analyst says a full recovery is on the cards. Moderna shares could return to $191 Eliana Merle now recommends buying Moderna shares as they can climb to $191 – a 60% upside from their previous close.

Moderna stock price forecast: UBS sees a 60% upside

UBS analyst Eliana Merle upgraded Moderna stock to Buy from Neutral, but trimmed the price target. The Covid and RSV businesses alone are worth $123 a share, she says.

Moderna Stock Is a Buy. The Pipeline Is Underappreciated, Says Analyst.

UBS upgraded Moderna Inc (NASDAQ:MRNA) to "buy" from "neutral" this morning, but also lowered its price targe to $191 from $221.

Moderna Stock Upgrade Has Call Traders Moving In

UBS upgraded its rating on vaccine maker Moderna MRNA, -1.64% to buy from neutral on valuation grounds, but cut its price target to $191 from $221. “We acknowledge the uncertainty around the commercial/endemic COVID market and uncertainty around '23 revenues, which has been a key investor focus and headwind,” said analysts led by Eliana Merle.

UBS upgrades Moderna to buy while cutting price target

Moderna shares delivered enormous gains during the first year and a half of the pandemic. Since then, though, the stock has suffered as investors worry about declining revenues.

Wall Street Says This Beaten-Down Stock May Climb Nearly 78%. Is That Too Optimistic?

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.

Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine

Moderna said on Thursday it has completed the submission of a regulatory application to the U.S. Food and Drug Administration for its updated COVID-19 vaccine to target subvariant XBB.1.5.

Moderna files for US FDA authorization of updated COVID vaccine

Moderna said the submission is based on the FDA's recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.

Moderna files for FDA approval of updated Covid vaccine for fall

Preliminary clinical data demonstrated a robust immune response by the company's XBB.1.5 monovalent vaccine against XBB descendent lineage viruses Pending authorization, Moderna's updated COVID-19 vaccine would be available in time for fall vaccination Supply readiness follows months of manufacturing to ensure timely and ample supply CAMBRIDGE, MA / ACCESSWIRE / June 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has completed submission of a regulatory application to the U.S. Food and Drug Administration for its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 (mRNA-1273.815). "The agility of our mRNA platform has enabled us to update Spikevax, Moderna's COVID-19 vaccine, to target XBB variants with speed and clinical rigor," said Stéphane Bancel, CEO of Moderna.

Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine

VanEck Vectors Biotech ETF

First Trust Morningstar Dividend Leaders Index Fund

First Trust Nasdaq Pharmaceuticals ETF 

Amplify Treatments Testing & Advancements ETF

iShares Core High Dividend ETF

Invesco Nasdaq Biotechnology ETF

Horizon Kinetics Medical ETF

Invesco Dynamic Pharmaceuticals ETF

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

Denali Therapeutics

Foghorn Therapeutics

Seres Therapeutics

Omega Therapeutics

Sana Biotechnology

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million from Flagship Pioneering Empress has identified and characterized 15 potential small molecule drugs in less than two years; it expects to file multiple Investigational New Drug (IND) applications within the next 24 months Murray McKinnon, Ph.D., former Global Head of J&J's World Without Disease Accelerator and Head of Immunology Discovery within Janssen Pharmaceuticals, appointed Chief Scientific Officer CAMBRIDGE, Mass.

News for Moderna Stock (MRNA)